UM Ventures announces collaboration between UM School of Medicine’s Dr. Frank Robb and Fina Biosolutions
July 11, 2013—PATH-Funded Public-Private Partnership Designed to Improve Vaccine Manufacturing Platform BALTIMORE, MD – University of Maryland (UM) Ventures announced today a collaboration between Frank Robb, Ph.D., at the Institute of Marine and Environmental Technology, and Department of Microbiology & Immunology at the University of Maryland School of Medicine, and Rockville, Maryland-based
June 12, 2013—We are still in Rockville in the heart of Montgomery County, Maryland Biotechnology.
April 19, 2013—Soybean peroxidase (SBP) is a direct substitute for HRP in immunoassays. SBP provides equal or superior signal compared with HRP, with lower background Greatly Improved thermostability “Glow” v “flash” in chemiluminescence – Low background, high signal – Less time needed for optimization – Less need for substrate enhancers
March 28, 2013—Fina BioSolutions is recognized by the Rockville Economic Development office for its contributions.
Andrew Lees will be the course director for the University of Maryland Biotechnology Research and Education Program
March 28, 2013—Andrew Lees, Scientific Director of Fina Biosoutions, will be the course director for the University of Maryland Biotechnology Research and Education Program course on downstream processing, June 6-8. For details, contact Ben Woodard, firstname.lastname@example.org
Fina Biosolutions Licenses Rights to its Vaccine Conjugation Technology for Development and Manufacturing of PNEUMOCOCCAL vaccines in China to Chengdu Institute of Biological Products Co., Ltd
August 19, 2012—Deal will accelerate development of affordable Pneumococcal Vaccines in China Rockville, Md. – Fina Biosolutions LLC, a research and development stage biotechnology company focused on developing affordable conjugate vaccines, and The Chengdu Institute of Biological Products Co., Ltd (CDIBP) announced their agreement to license Finabio’s conjugate vaccine technology for the
University of Maryland Center for Vaccine development receives Wellcome Trust grant for a conjugate vaccine using chemistry developed by Andrew Lees, Scientific director of FinaBio Solutions
June 28, 2012—New Vaccine Will Be Fast-Tracked By $4 Million Award from Wellcome Trust The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has received a $4 million Strategic Translation Award from the prestigious Wellcome Trust to support a collaboration with Bharat Biotech for clinical development of a new conjugate
May 2, 2012—Andrew Lees, Scientific Director at Fina BioSolutions is the course director for Downstream Processing & Protein Purification Workshop to be held June 6-8, 2012 at the University of Maryland, College Park, Maryland. Registration and more information.
Fina BioSolutions presents at MinHai Biotech Beijing and Chengdu Biological Institute on bioconjugation chemistry.
October 19, 2011—Pneumococcal Conjugate Vaccine Symposium. PATH sponsored. Beijing, China Fina BioSolutions presents at MinHai Biotech Beijing and Chengdu Biological Institute on bioconjugation chemistry.
September 29, 2011—Andrew Lees will be speaking on Membrane Chromatography for the purification of Conjugate Vaccines. Sartorius Downstream Technical Forum, Rockville, MD